Publikationen in Zusammenarbeit mit Forschern von Hannover Medical School (17)

2023

  1. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

    The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422

  2. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial

    HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6

  3. Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309

2022

  1. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 13, pp. 4716-4726

  2. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

    Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693

  3. Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255](S0923753419317119)(10.1093/annonc/mdy308)

    Annals of Oncology

  4. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

2021

  1. AdrA as a Potential Immunomodulatory Candidate for STING-Mediated Antiviral Therapy That Required Both Type I IFN and TNF-α Production

    Journal of immunology (Baltimore, Md. : 1950), Vol. 206, Núm. 2, pp. 376-385

  2. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

    Annals of Oncology

2020

  1. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach

    Hepatology, Vol. 72, Núm. 1, pp. 198-212

2018

  1. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 29, pp. iv238-iv255

2017

  1. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease

    Journal of the American Medical Directors Association, Vol. 18, Núm. 12, pp. 1097.e11-1097.e24

  2. Transarterial chemo-embolisation of hepatocellular carcinoma: Impact of liver function and vascular invasion

    British Journal of Cancer, Vol. 116, Núm. 4, pp. 448-454

2016

  1. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: Application of the ALBI grade

    British Journal of Cancer, Vol. 114, Núm. 7, pp. 744-750

  2. Prognostic assessment in COPD without lung function: The B-AE-D indices

    European Respiratory Journal, Vol. 47, Núm. 6, pp. 1635-1644

2010

  1. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma

    European Journal of Gastroenterology and Hepatology, Vol. 22, Núm. 4, pp. 391-398

2009

  1. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients

    Liver Transplantation, Vol. 15, Núm. 2, pp. 136-147